Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus paracasei GM-080 + fluticasone propionate
- Development stage
- Preclinical
- Lead developer
- GenMont Biotech
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Small Molecules
- Administration
- Oral, Intranasal, Inhalation
01
Overview
This is a combination product containing two active ingredients:
- Lactobacillus paracasei GM-080 (also known as Lacticaseibacillus paracasei GM-080), a probiotic strain shown to modulate immune responses, reduce airway inflammation, and alleviate symptoms of allergic diseases such as allergic rhinitis. It acts by stimulating interferon-gamma (IFN-γ) and interleukin-12 (IL-12) production, enhancing Th1 immune responses, and reducing IgE-mediated inflammation. The strain is considered safe, non-toxic, and able to survive gastrointestinal transit.
- Fluticasone propionate, a synthetic glucocorticoid corticosteroid widely used as an anti-inflammatory agent in the treatment of allergic rhinitis and asthma. It works by binding to the glucocorticoid receptor to suppress pro-inflammatory gene expression.
The combination aims to provide both immunomodulatory effects from the probiotic component and potent anti-inflammatory action from the corticosteroid for enhanced management of airway inflammatory conditions such as allergic rhinitis.
- Other names
- Lacticaseibacillus paracasei GM-080 + fluticasone propionate
02
Targets
Beyond the preview
Go deeper on Lactobacillus paracasei GM-080 + fluticasone propionate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus paracasei GM-080 + fluticasone propionate.